CTSB and early-onset autosomal dominant Alzheimer disease: These findings suggest that increasing endogenous Cathepsin B activity could potentially reduce Aβ levels, particularly Aβ1-42, and protect against Alzheimer’s disease-related deficits (Sun et al., 2008).